Skip to main content
. 2021 Apr 22;11:669066. doi: 10.3389/fonc.2021.669066

Figure 5.

Figure 5

Candida and Zymosan exacerbate and accelerate dysplasia and hyperplasia. (A) 4-NQO was administered in WT or TLR-2 KO C57BL/6 mice as in Figure 3A (6 mice/group). Zymosan (1mg), Candida (107 blastospores), or both were applied sublingually under anesthesia every week between the 4th and 8th weeks of 4-NQO administration. H&E staining was performed to assess dysplasia and hyperplasia (A). Immunohistochemistry and flow cytometry were performed. Statistics based on dysplasia and hyperplasia score (B), IL-1β immunohistochemistry (C), flow cytometry staining for Treg assessment (D), and OSCC scores (E). OSCC scores were assigned based on hyperplasia, invasive hyperkeratosis, and nests after 20 weeks after 4-NQO administration. Statistics show Mean +/- SEM (Mann-Whitney test *P < 0.05, **P < 0.05, ***P < 0.005, n.s, non-significant).